CD Skripsi
Sintesis Dan Studi Molecular Docking Senyawa Hidrazon Turunan 3-Metoksi-4-(Propoksi) Benzaldehid Dan Isoniazid Sebagai Antikanker Payudara
Hydrazone is a substituted compound with stable imine-type that has an azomethine groups (-NH-N=C-R-). These compounds have interesting biological properties, such as anti-inflammatory, antituberculosis, antitumor, antimicrobial activity, anticancer and others. The hydrazone compound with the IUPAC name (E)-N'-(3-methoxy-4-(propoxy)benziliden) isonicotinohydrazide and named as HDZ-ISZ has been successfully synthesized in two-step of reaction process. The initial stage involved the formation of 3-methoxy-4-(propoxy)benzaldehyde (Vn-sb) through the O-alkylation reaction of propargylated substituted vanillin with a yield of 72%. The final stage entailed the formation of HDZ-ISZ compound through the condensation reaction between 3-methoxy-4-(propoxy)benzaldehyde and isoniazide using the stirring and heating methods. The yield obtained from the synthesized hydrazone was 64%. The synthesized compounds were confirmed by characterization with ultraviolet spectroscopy (UV), Fourier transform infra red (FTIR), 1H-nuclear magnetic resonance (1H-NMR) and liquid chromatography mass spectrometry (LC-MS). The activity of the product as a breast anticancer drug was identified in silico. Molecular docking studies were performed on the pure compound against estrogen receptor-α (PDB ID: 8DVB) with 4-hydroxytamoxifen (4-OHT) as a positive control. The results of the molecular docking studies of the hydrazone have slightly low binding free energy and inhibition constants compared to the results of 4-OHT against estrogen receptor-α (ΔGbind = -9.14 kcal/mol; Ki = 0.2 μM) and 4-OHT ligand (ΔGbind = -9.3 kcal/mol; Ki = 0.151 μM), indicating that the hydrazone (HDZ-ISZ) possesses a weak biological activity as breast anticancer.
Tidak tersedia versi lain